TGF-ALPHA PROCESSING IN ORAL CANCER
口腔癌中的 TGF-α 处理
基本信息
- 批准号:6651761
- 负责人:
- 金额:$ 14.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-06-01 至 2003-05-31
- 项目状态:已结题
- 来源:
- 关键词:athymic mouse cell line growth factor receptors metalloendopeptidases mouth neoplasms neoplastic transformation phosphorylation posttranslational modifications protein kinase protein protein interaction protein purification protein structure protein structure function proteolysis squamous cell carcinoma transforming growth factors
项目摘要
Cancer cells are subject to autocrine receptor stimulation by endogenous growth factors, and this stimulation contributes to malignant transformation and cancer development. Oral carcinoma cells often show increased (EGFR). Clinical correlation and in vitro and in vivo studies strongly suggest that increased EGFR stimulation by TGF-alpha contributes to carcinogenesis. TGF-alpha is made as a transmembrane growth factor, which undergoes regulated ectodomain cleavage or "shedding" to release soluble and diffusible TGF-alpha. Transgenic experiments suggest that this cleavage of transmembrane TGF-alpha is required for its ability to stimulate carcinoma development. TGF-alpha ectodomain shedding is mediated by TACE, a transmembrane metalloprotease, which was originally discovered for its ability to mediate TNF-alpha cleavage. The mechanisms that activate TACE and consequent TGF-alpha cleavage were unknown until recently We have recently shown that growth factors, which activate tyrosine kinase receptors, induce ectodomain shedding of TGF-alpha as well as TNF- alpha and L-selectin Growth factor-induced TGF-alpha ectodomain shedding is mediated through activation of the Erk MAP kinase pathway and does not require new protein synthesis. We have also shown that the cytoplasmic domain of TACE is phosphorylated in response to growth factor stimulation and that the cytoplasmic domain of TGF-alpha ectodomain cleavage. This proposal now builds on these findings and is aimed at characterizing the signaling mechanism(s) that lead to activation of TGF-alpha shedding and its role in oral carcinoma development. We have subdivided the proposal in four Aims. In Aim 1, we propose to characterize the growth factor-induced phosphorylation of TACE and its role in TACE activation and ectodomain shedding. In Aim 2, we propose two different approaches to identify, clone and characterize the kinase, which phosphorylates TACE and in this way activates TACE mediated shedding in response to growth factor stimulation. In Aim 3, we propose to identify and functionally characterize proteins that interact with TACE and, in this way regulate TACE activation and ectodomain shedding. Finally, in Aim 4, we will evaluate the role of TGF-alpha and its ectodomain cleavage, as a result of TACE activation and ectodomain shedding. Finally, in Aim 4, we will evaluate the role of TGF-alpha and its ectodomain cleavage, as a result of TACE activation in carcinogenesis and tumor development of oral squamous carcinoma in vivo.
癌细胞受到内源性生长因子的自分泌受体刺激,这种刺激有助于恶性转化和癌症发展。口腔癌细胞常表现为EGFR的增加。临床相关性以及体外和体内研究强烈表明,TGF-α对EGFR刺激的增加有助于致癌作用。TGF-α被制成跨膜生长因子,其经历受调节的胞外域切割或“脱落”以释放可溶性和可扩散的TGF-α。转基因实验表明,这种跨膜TGF-α的切割是其刺激癌发展的能力所必需的。TGF-α胞外域脱落由TACE介导,TACE是一种跨膜金属蛋白酶,最初发现其能够介导TNF-α切割。激活TACE和随后的TGF-α切割的机制直到最近才被了解。我们最近已经表明,激活酪氨酸激酶受体的生长因子诱导TGF-α以及TNF-α和L-选择素的胞外域脱落。生长因子诱导的TGF-α胞外域脱落是通过激活Erk MAP激酶途径介导的,并且不需要新的蛋白质合成。我们还表明,TACE的胞质结构域响应于生长因子刺激而磷酸化,并且TGF-α胞外域的胞质结构域裂解。该提案现在建立在这些发现的基础上,旨在表征导致TGF-α脱落激活的信号传导机制及其在口腔癌发展中的作用。我们将该建议细分为四个目标。在目标1中,我们提出了TACE的生长因子诱导的磷酸化及其在TACE激活和胞外域脱落中的作用。在目标2中,我们提出了两种不同的方法来识别,克隆和表征激酶,其磷酸化TACE并以这种方式激活TACE介导的脱落以响应生长因子刺激。在目标3中,我们提出鉴定和功能表征与TACE相互作用的蛋白质,并以这种方式调节TACE活化和胞外域脱落。最后,在目标4中,我们将评估由于TACE激活和胞外域脱落而导致的TGF-α及其胞外域切割的作用。最后,在目标4中,我们将评估TGF-α及其胞外域切割的作用,作为TACE激活在体内口腔鳞状细胞癌发生和肿瘤发展中的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RIK M DERYNCK其他文献
RIK M DERYNCK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RIK M DERYNCK', 18)}}的其他基金
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
- 批准号:
9105649 - 财政年份:2016
- 资助金额:
$ 14.53万 - 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
- 批准号:
9894637 - 财政年份:2016
- 资助金额:
$ 14.53万 - 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
- 批准号:
9452037 - 财政年份:2016
- 资助金额:
$ 14.53万 - 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
- 批准号:
9237246 - 财政年份:2016
- 资助金额:
$ 14.53万 - 项目类别:
PRMT1 MEDIATED ARG METHYLATION OF INHIBITORY SMADS IN TGF-BETA SIGNALLING
PRMT1 介导 TGF-β 信号传导中抑制性 SMAD 的 ARG 甲基化
- 批准号:
8363822 - 财政年份:2011
- 资助金额:
$ 14.53万 - 项目类别:
PRMT1 MEDIATED ARG METHYLATION OF INHIBITORY SMADS IN TGF-BETA SIGNALLING
PRMT1 介导 TGF-β 信号传导中抑制性 SMAD 的 ARG 甲基化
- 批准号:
8169818 - 财政年份:2010
- 资助金额:
$ 14.53万 - 项目类别:
Regulatory non-Smad signaling in TGF-b-induced epithelial-mesenchymal transition
TGF-b 诱导的上皮间质转化中的调节性非 Smad 信号传导
- 批准号:
9197271 - 财政年份:2009
- 资助金额:
$ 14.53万 - 项目类别:
TGF-beta-induced non-Smad signaling events and cancer cell behavior
TGF-β诱导的非Smad信号传导事件和癌细胞行为
- 批准号:
7565384 - 财政年份:2009
- 资助金额:
$ 14.53万 - 项目类别:
TGF-b family signaling in cardiomyocyte differentiation from embryonic stem cells
胚胎干细胞向心肌细胞分化中的 TGF-b 家族信号传导
- 批准号:
7738990 - 财政年份:2009
- 资助金额:
$ 14.53万 - 项目类别:
Non-Smad Mechanisms of TGFBeta Signaling
TGFBeta 信号转导的非 Smad 机制
- 批准号:
7827981 - 财政年份:2009
- 资助金额:
$ 14.53万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 14.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 14.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 14.53万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 14.53万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 14.53万 - 项目类别:














{{item.name}}会员




